RE: SPA6 Nov 2020 14:48
Eva ,
Have you had a few glasses today ?
Avion NEVER said that they would put in more if necessary , please provide a source if you can
rns
Avion has agreed to fund the full costs of the new optimised international Phase III trial for Lupuzor™ in lupus patients, based on an agreed level of expected costs up to $25 million. It is anticipated that this new Phase III trial will commence in 2020, following agreement of the trial design between Avion, ImmuPharma and the FDA. Following recruitment of patients (to include US, Europe and elsewhere), it is envisaged that this will be a 52-week trial. Both companies will jointly steer the clinical program.
Avion will fund the full expected costs of the new Phase III trial up to $25 million.
UP TO, twice written .....